A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT01074125
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT01074125
-
- Other papers using this trial's data
- Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01074125. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2010-11 (actual). Results posted on 2014-12-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
- Condition
- Hyperphosphatemia
- Condition
- End-Stage Renal Disease
- Intervention (Drug)
- ferric citrate
- Lead sponsor
- Keryx Biopharmaceuticals
- Collaborator
- Collaborative Study Group (CSG)
Record details
- Record id
cardio:ct-nct01074125- Content hash
a75de514071f4543d203fbd74c5c786c666043ec633a796b9fc4aefe484046e6